Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) shares traded down 0.5% on Monday . The company traded as low as $1.88 and last traded at $1.95. 9,989 shares were traded during mid-day trading, a decline of 44% from the average session volume of 17,924 shares. The stock had previously closed at $1.96.
Alaunos Therapeutics Stock Performance
The company’s 50-day moving average price is $2.20 and its 200-day moving average price is $3.64.
Alaunos Therapeutics Company Profile
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
See Also
- Five stocks we like better than Alaunos Therapeutics
- ESG Stocks, What Investors Should Know
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- What to Know About Investing in Penny Stocks
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- What is a buyback in stocks? A comprehensive guide for investors
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
